Everyone Healthy Bringing clearer health knowledge to everyone.

Everyone Healthy Library

Tropical Spastic Paraparesis

Condition / disease reference page from the Everyone Healthy database.

Connected health information

Explore this condition in a clear order

Condition overview

Attributes

Commonalityis rare

Linked signs and symptoms

0

No related signs or symptoms are listed yet.

Linked drugs / medications

0

No linked drugs are listed yet.

Treatments, therapies and supportive options

0

Grouped by treatment type. These are educational database links, not personal treatment recommendations. Evidence labels are shown only where stored in the EH database.

No linked treatment or supportive options are listed yet.

Linked diagnostic tests and investigations

0

No linked diagnostic tests are listed yet.

Biological and test markers

0

This visual map uses existing EH database links to show biological agents and lab markers reported as increased, decreased, or associated with this condition. These are educational relationships only; test results must be interpreted by a qualified clinician because ranges vary by lab, method, age, sex and clinical context.

No biological marker links are listed yet for this condition.

Introduction / full article

Tropical Spastic Paraparesis

ID 1796

Tropical Spastic Paraparesis

 

 

 

Tropical spastic paraparesis (TSP) is an infection of the spinal cord by Human T-lymphotropic virus resulting in paraparesis, weakness of the legs. As the name suggests, it is most common in tropical regions, including the Caribbean and Africa.


Presentation

Patients with HAM/TSP may also exhibit uveitis (inflammation of the uveal tract of the eye), arthritis (inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung tissues), polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). Co-factors that may play a role in transmitting the disorder include being a recipient of transfusion blood products (especially before 1989), breastmilk feeding from a seropositive mother, intravenous drug use, or being the sexual partner of a seropositive individual for several years. Not every HTLV-1 seropositive carrier will become a HAM/TSP patient. Fewer than 5% will exhibit neurological dysfunction or, eventually, hematological malignancy such as adult T-cell leukemia/lymphoma, suggesting that other host or viral factors are responsible for disease onset.

 

Symptoms


Prevention

Blood transfusion products are screened for HTLV-1 antibodies.


Treatment

There is no established treatment program for HAM/TSP although some patients may be given steroids. Clinical studies using interferon alpha and plasmapheresis have not shown significant patient improvement. Spasticity may be treated with lioresal or tizanidine. Urinary dysfunction should be treated with self-catheterization or oxybutynin.